Alpibectir clinical trials
How each study uses alpibectir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the alpibectir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
Often tested with
Tested in the same studies.
Ethionamide (1) · BTZ-043 (1) · Rifampin (1) · Isoniazid (1) · Pyrazinamide (1) · Moxifloxacin (1) · Ethambutol (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test alpibectir.
- Oct 2027PanACEA - STEP2C -01Phase 2 · Michael Hoelscher
Studies
Open first, then newest update. How each study uses alpibectir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- PanACEA - STEP2C -01RecruitingPhase 2Michael HoelscherNCT05807399Written as Alpibectir (GSK3729098)
- A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With EthionamideRecruitingPhase 2TASK Applied ScienceNCT06748937Written as Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD
- A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098CompletedPhase 2TASK Applied ScienceNCT05473195Written as BVL-GSK098 9mg
Codes
What other systems call alpibectir · ClinicalTrials.gg INT016213
- UNII (FDA) CC5WUX826WALPIBECTIRConfirmed FDA, Wikidata
- Wikidata Q138780407alpibectirConfirmed FDA, Wikidata
- NCI Thesaurus C190427AlpibectirOne source FDA
- DrugBank DB21561One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | CC5WUX826W | ALPIBECTIR | Confirmed FDA, Wikidata |
| Wikidata | Q138780407 | alpibectir | Confirmed FDA, Wikidata |
| NCI Thesaurus | C190427 | Alpibectir | One source FDA |
| DrugBank | DB21561 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.